Tag:
Quintiles
Latest Headlines
Latest Headlines
Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement
Based on the findings published in Quintiles' annual "New Health Report," payers want to get the ball rolling sooner to get drugs approved faster.
Pike picked to sit at Quintiles peak
Tom Pike is taking the helm at biopharma services giant Quintiles. Founder Dennis Gillings is staying on as executive chairman.
UPDATED: Tom Pike joins Quintiles as new CEO
Pike, a newcomer to Quintiles, will begin his new job April 30.
Quintiles touts new virtual research technology
Quintiles has agreed to start promoting access to Archimedes' computer simulation model.
Social media jump-starts stalled patient recruitment efforts
Drug developers have picked up social media and online tools to find patients for clinical trials, realizing benefits beyond just getting qualified participants into their studies. Groups have found other perks such as the ability to stay connected with patients and build a network of people to tap for future recruitment drives.
Quintiles partners with Russians on new drug development ventures
A venture group backed by the Russian government and tasked with building a drug development industry in the country is partnering with Quintiles to go to work on the clinical trial end of the...
Russian biotech VC and Quintiles to join forces on pharma services startups
Quintiles has revealed a partnership with Russian Venture Company (RVC) Biofund as part of the CRO giant's ongoing efforts in Russia.
Quintiles $300M loan plan yields info on big year for outsourcing
Quintiles Transnational aims to borrow $300 million in a secured term loan to help fund a $335 million dividend for shareholders, after the company posted double-digit revenue growth last year,...
Quintiles to offer guidance on navigating Asian drug projects
All the big CROs have made a practice of highlighting their full-service expertise in drug development in recent years. They've been styling themselves as consultants capable of guiding companies...
Quintiles report highlights the challenge of the 'value proposition'
It's become axiomatic in drug development circles that unless you're looking to move the dial on treatment standards in your chosen field, you're in the wrong business. Me-too drugs are out. Proving
